Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of "Buy" by Analysts

Key Points

• Analysts give Eyepoint a consensus "Buy" rating from eight firms (1 sell, 5 buy, 2 strong buy) with an average 1‑year price target of $32.20.
• Large institutions have built sizable positions—Janus Henderson initiated a ~$53.7M stake while Paradigm Biocapital and OrbiMed also entered, and Suvretta and Federated Hermes materially increased holdings—leaving about 99.41% of the stock owned by hedge funds and other institutional investors.
• Eyepoint recently missed quarterly estimates (EPS -$0.81 vs. -$0.78; revenue $0.62M vs. $1.01M); the stock trades near $13.34 with a $1.12B market cap and a 12‑month range of $5.30–$19.11.

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has been given a consensus rating of "Buy" by the eight research firms that are covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $32.20.

EYPT has been the topic of several analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Eyepoint Pharmaceuticals in a research note on Tuesday, April 21st. Citigroup raised their price target on shares of Eyepoint Pharmaceuticals from $31.00 to $35.00 and gave the stock a "buy" rating in a research note on Monday, March 9th. HC Wainwright raised their price target on shares of Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, March 5th. Finally, Chardan Capital raised their price target on shares of Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a "buy" rating in a research note on Wednesday, March 4th.

Insider Transactions at Eyepoint Pharmaceuticals

In related news, insider Ramiro Ribeiro sold 2,437 shares of the business's stock in a transaction that occurred on Friday, April 17th. The shares were sold at an average price of $15.00, for a total value of $36,555.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.46% of the company's stock.

Institutional Investors Weigh In On Eyepoint Pharmaceuticals

A number of institutional investors have recently bought and sold shares of EYPT. Janus Henderson Group PLC purchased a new stake in Eyepoint Pharmaceuticals in the fourth quarter valued at approximately $53,658,000. Paradigm Biocapital Advisors LP purchased a new stake in Eyepoint Pharmaceuticals in the third quarter valued at approximately $28,556,000. Orbimed Advisors LLC purchased a new stake in Eyepoint Pharmaceuticals in the third quarter valued at approximately $25,575,000. Suvretta Capital Management LLC grew its holdings in Eyepoint Pharmaceuticals by 26.4% in the fourth quarter. Suvretta Capital Management LLC now owns 7,827,685 shares of the company's stock valued at $143,012,000 after purchasing an additional 1,634,970 shares during the period. Finally, Federated Hermes Inc. grew its holdings in Eyepoint Pharmaceuticals by 36.3% in the fourth quarter. Federated Hermes Inc. now owns 6,017,433 shares of the company's stock valued at $109,938,000 after purchasing an additional 1,601,101 shares during the period. 99.41% of the stock is currently owned by hedge funds and other institutional investors.

Eyepoint Pharmaceuticals Price Performance

Eyepoint Pharmaceuticals stock opened at $13.34 on Friday. Eyepoint Pharmaceuticals has a 12-month low of $5.30 and a 12-month high of $19.11. The stock has a market capitalization of $1.12 billion, a P/E ratio of -4.22 and a beta of 1.76. The firm's 50-day moving average is $14.51 and its two-hundred day moving average is $14.56.

Eyepoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.78) by ($0.03). Eyepoint Pharmaceuticals had a negative return on equity of 88.31% and a negative net margin of 739.39%.The firm had revenue of $0.62 million for the quarter, compared to analyst estimates of $1.01 million. As a group, analysts forecast that Eyepoint Pharmaceuticals will post -3.01 EPS for the current year.

Eyepoint Pharmaceuticals Company Profile

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company's proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint's commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint's lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.